CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 300 enrolled
Drug / intervention
Apixaban +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02585713
NCT02585713Phase 3Completed
CompareCT.gov

A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism

Academic and Community Cancer Research United·interventional·Posted Oct 23, 2015·Updated Aug 4, 2020

In Brief

A Phase 3 clinical trial evaluating Apixaban, Dalteparin, and 1 other intervention for Cerebral Vein Thrombosis and 11 related conditions. Completed, enrolled 300 participants across 18 sites.

Detailed Summary

This randomized phase III trial studies the side effects of and compares apixaban and dalteparin in reducing blood clots in patients with cancer-related venous thromboembolism. Venous thromboembolism is a condition in which a blood clot forms in a vein and then breaks off and moves through the bloodstream. Patients with cancer are at increased risk for venous thromboembolism. Apixaban and dalteparin are drugs used to prevent blood clots from forming or to treat blood clots that have formed. It is not yet known whether apixaban or dalteparin is more effective in reducing blood clots in patients with cancer related venous thromboembolism. ADAM-VTE

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCerebral Vein Thrombosis, Deep Vein Thrombosis, Gonadal Thrombosis, Hepatic Thrombosis, Malignant Neoplasm, Mesenteric Thrombosis, Metastatic Malignant Neoplasm, Portal Vein Thrombosis, Pulmonary Embolism, Renal Vein Thrombosis, Splenic Thrombosis, Venous Thromboembolism
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 23, 2015
Enrollment StartNov 20, 2015
Primary CompletionApr 2, 2018
Study CompletionDec 24, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 10.7 years ago

Interventions

Apixabandrug

Given PO

Dalteparindrug

Given SC

Questionnaire Administrationother

Ancillary studies